Navigation path

Pharmaceuticals - Union Register


Register of orphan medicinal products


Product information


EU orphan designation number: EU/3/13/1125   
Active ingredient: (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Indication: Treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma
Sponsor: Voisin Consulting S.A.R.L.
64 avenue Pierre Grenier, 92100 Boulogne Billancourt, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/04/2013 Orphan designation EMA/OD/196/12 (2013)2562 of 26/04/2013
13/11/2015 Transfer of orphan designation EMA/OD/196/12/T/01 (2015)8036 of 11/11/2015
17/03/2016 Corrigendum (2016)1716 of 15/03/2016
28/09/2016 Transfer of orphan designation EMA/OD/196/12/T/02 (2016) 6308 of 26/09/2016
22/05/2017 Change of name and/or address of sponsor